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Abstract
Background: The objective was to identify separate cognitive domains in the standard assessment
tools (MMSE, ADAS-Cog) and analyze the process of decline within domains during three years in
Alzheimer's disease (AD) patients with donepezil treatment.
Method: AD patients (n = 421) were recruited from a clinical multi-centre study program in
Sweden. Patients were assessed every six months during three years. All patients received
donepezil starting directly after study entry. After dropouts, 158 patients remained for analyses
over three years. Data for the other patients were analysed until they dropped out (4 groups based
on length in study).
Results: Factor analyses of all items suggested that there were three intercorrelated factors: a
General, a Memory and a Spatial factor for which we constructed corresponding domains. Overall
there was a cognitive improvement at six months followed by a linear drop over time for the three
domains. Some group and domain differences were identified. Patients who remained longer in the
study had better initial performance and a slower deterioration rate. The early dropouts showed
no improvement at six months and many dropped out due to side effects. The other groups
displayed a performance improvement at six months that was less pronounced in the Memory
domain. Before dropping out, deterioration accelerated, particularly in the Spatial domain.
Conclusion: The course of illness in the three domains was heterogeneous among the patients.
We were not able to identify any clinically relevant correlates of this heterogeneity. As an aid we
constructed three algorithms corresponding to the cognitive domains, which can be used to
characterize patients initially, identify rapid decliners and follow the course of the disease.
Background
Alzheimer's disease (AD) is a neurodegenerative disorder
characterised by disturbances in many areas, including
higher cognitive functions like memory, orientation and
attention. AD is the predominant cause of dementia, a
major source of disability and suffering among the eld-
erly, and causing enormous and increasing economic
costs for society [1-3]. At present, there is no effective cure
available for AD. Symptomatic therapy, usually by means
of choline esterase inhibitors (ChEI) is used on a regular
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basis. Short-term placebo controlled studies have
reported small to moderate effect sizes of ChEI treatment
on cognition in AD patients [4-7].
Almost all clinical trials on symptomatic therapy for AD
use the Mini-Mental State Examination (MMSE) and/or
the Alzheimer's Disease Assessment Scale – Cognitive sub-
scale (ADAS-Cog). Most studies follow patients only over
six months. Existing longitudinal studies support that the
cognitive advantage gained by treatment established in
short-term studies remains up to four years [8-14], how-
ever replications are required. Studies of more than three
years often suffer from high dropout rates ranging from 67
to 96 percent [9-11]. What distinguishes patients that
actually complete a three-year study from those who drop
out, for example in pattern of cognitive reduction, needs
to be further investigated.
AD is a disease that progresses through different brain lay-
ers, which implies changes in the cognitive symptom pro-
file over time. One problem is that most studies on ChEI
treatment do not present cognitive outcome measures
divided into different domains [15]. To properly evaluate
these treatments, it is important to assess changes in spe-
cific cognitive domains, mapped over time. Such data may
provide hints as to the causal mechanisms and will have
consequences for planning interventions for the individ-
ual patient, and for developing support systems for AD
patients on the societal level. One standard way of group-
ing items into homogenous categories is by factor analy-
sis. We have found only few factor analytic studies on
MMSE or ADAS-Cog, reporting two or three factors typi-
cally reflecting general functioning, concentration, mem-
ory, language or praxis [16-20]. Comparisons among
these factor analytic studies are difficult for technical rea-
sons; mainly differences in the rotation procedures, and
no authors have based their factor analyses on combined
MMSE and ADAS-Cog data.
The present study aims at identify salient cognitive
domains in the MMSE and ADAS-Cog instruments com-
bined, and to describe patterns of change in patients with
AD during three years of therapy by the ChEI donepezil.
Furthermore we wanted to identify clinically relevant dif-
ferences between 3-year completers and patients who
dropped out before study end, including analysis of APOE
genotype. We also wanted to construct algorithms within
different cognitive domains, based on the patient material
at study entry as a norm group. Such algorithms can be
expected to be of use in the clinic as well as in treatment
research.
Method
The present study is part of the Swedish Alzheimer Treat-
ment Study (SATS), an ongoing, prospective multi-centre
study, designed to evaluate the long-term effect of ChEI
treatment in patients with AD in a routine clinical setting.
The SATS is run in ten memory clinics in Sweden, admin-
istrated from the Memory Clinic at U-MAS, Malmö. Pres-
ently more than 1,000 patients have been included in the
study. Detailed information about the SATS study pro-
gram is presented elsewhere [21].
Subjects
This study is based on 421 AD patients recruited from the
first 435 consecutive subjects with donepezil treatment
included in the SATS study program between 1997 and
2001 (14 subjects were excluded due to missing values,
v.i.). Inclusion criteria were clinical AD diagnosis accord-
ing to the Diagnostic and Statistical Manual of Mental
Disorders, 4th edition (DSM-IV) [22], and probable or
possible AD, according to the criteria of the National Insti-
tute of Neurological and Communicative Disorders and
Stroke and the Alzheimer's Disease and Related Disorders
Association (NINCDS-ADRDA) [23], age above 40, living
at home, either with a family member or having a car-
egiver. Exclusion criteria were other causes of dementia
than AD, being already on ChEI treatment at study entry
and contraindications to donepezil treatment. Other
medications than antidementia ones were allowed, and
the doses were recorded.
All participants and their caregivers provided written
informed consent. The study was designed in accordance
with the Helsinki Declaration and approved by the Ethics
Committee at Lund University.
Measures
MMSE
The MMSE was constructed to measure the cognitive
aspects of mental status [24]. It includes ten items: Orien-
tation, Registration, Attention (-Calculation), Recall,
Naming, Repetition, Comprehension, Reading Ability,
Writing Ability and Visual Construction. Sometimes the
six latter are referred to as the Language category. The
MMSE scale ranges from 0 to 30, the higher the score the
better cognitive performance.
ADAS-Cog
The ADAS-Cog was developed by Rosen and co-workers
[25] in order to measure cognitive aspects of AD. The
standard ADAS-Cog scale includes eleven items, of which
seven are short cognitive tests: Word Recall, Naming
(objects and fingers), (Following) Commands, Construc-
tional Praxis, Ideational Praxis, Orientation and Word
Recognition, and four are scales rated by the clinician:
Remembering Test Instructions, Spoken Language Ability,
Word-finding Difficulty and Comprehension (of Spoken
Language) [26]. The majority of studies with ADAS-Cog
use the standard scale described above, ranging from 0 toBMC Neurology 2009, 9:7 http://www.biomedcentral.com/1471-2377/9/7
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70. The version of ADAS-Cog used in the SATS study also
comprises the items Delayed Word Recall and the rating
scale Concentration (Distractibility) (max 85 points). In
this study, all thirteen ADAS-Cog items were analysed as
single items. If nothing else is stated, the standard eleven-
item ADAS-Cog scale was used as a sumscore to enable
comparisons to other studies. The higher the ADAS-Cog
score the more cognitive impairment.
Genetics
The Apolipoprotein E genotype (APOE) has alleles with
different combinations of variants ε2, ε3 or ε4. A pattern
comprising one, or predominantly two, ε4 alleles has
been suggested to be associated with AD. In this study, the
variable APOE was dichotomous, as presence of at least
one ε4 allele or not.
Duration of illness
Duration of illness was estimated by the treating physi-
cian through a clinical interview with the patient and car-
egiver about debut of the first AD symptoms, at their first
visit at the memory clinic.
Procedure
Before inclusion in the study, patients were thoroughly
examined to rule out other causes of dementia than AD.
Prior to donepezil (Aricept®) treatment, the patients were
tested with a study entry battery, including MMSE and
ADAS-Cog. Two months after study entry the patients
were tested by MMSE a second time. Every six months
after study entry, they were repeatedly tested by both
MMSE and ADAS-Cog up to end of study (three years).
Thus, patients were tested, at most seven times by ADAS-
Cog and eight times by MMSE.
All decisions regarding medication, dosage etc. were made
by the treating physician according to clinical judgment.
At study entry, all subjects received 5 mg donepezil per
day. Over time an increasing number of patients were
treated by the maximum dose of 10 mg. After 12 months
a majority received 10 mg.
Statistical analysis
In a first phase of the analysis, data were scanned for miss-
ing values and outliers. Since our statistical analyses
require complete results for all test sessions, missing val-
ues were replaced for patients having at most 30 percent
missing values at MMSE and ADAS-Cog (up to their last
test session before eventual dropout). Fourteen patients
with more than 30 percent missing values were excluded,
leaving 421 patients for analysis. For MMSE and ADAS-
Cog sumscores, missing values were replaced only for 3-
year completers (N = 158). All missing data were replaced
by predicted values as the results of linear regression anal-
yses based on the other test (MMSE/ADAS-Cog) at the
same test session and earlier and later test results for both
tests as independent factors (4.4% of all values in MMSE
and 6.4% in ADAS-Cog were replaced this way; r varied
between .80 and .97). Item scores were not replaced.
Replacement of data for cognitive domains was per-
formed for 3-year completers (with max 4/14 tests miss-
ing), for 2-year completers (max 3/10 tests missing) etc.
Again, values were predicted by linear regression analyses
based on the other tests items at the same session, earlier
and later domain scores etc. (r varied between 0.95 and
1.0). In total 9.8 percent of the domain variables were
replaced this way. Four patients were on one test session
each judged as extreme outliers (the results differed a lot
from earlier and later results). These values were replaced
in the same way as described above.
Data were analysed by standard statistical methods (SPSS
15.0) and by latent class modeling analysis (Latent Gold
4.0, [27]). The analyses on MMSE and ADAS-Cog sum-
scores were based on the 3-year completers (N = 158), and
results on item level on 118 subjects for MMSE and 100
subjects for ADAS-Cog, for which there were complete
item data. Homogeneity was assessed by Cronbach's
alpha, which is equivalent to an icc value as computed by
SPSS 15.0. In order to define cognitive domains, principal
component factor analyses were performed on all items
(MMSE and ADAS-Cog combined), with oblique rotation
(Promax), and checked by the latent class modeling factor
analysis, which is non-parametric. Details are provided in
the Results section. An alpha level of p < .05 was used for
all statistical tests.
Results
Group characteristics and dropout analysis
At study entry, 421 subjects were included. Over the fol-
lowing years patients dropped out as depicted in Figure 1,
and for various reasons (v.i.). At study end 158 (38%)
patients were available for analyses of changes in parame-
ters over the whole time period.
Dropout causes were: admission to nursing home (24%),
change of therapy (17%), suspected side-effect (13%),
poor compliance (9.9%), deceased (9.5%), withdrawn
informed consent (9.5%), intercurrent somatic disease
(6.1%) and other causes (11%). For details regarding
drop-out in the SATS, see Wallin et al. [21]. Dropping out
due to side effects was strongly overrepresented among
patients who participated only in the study entry test-ses-
sion (χ2 (4) = 84.8, p < .001); otherwise there were no sig-
nificant effects in terms of reason for dropout.
Study entry characteristics of groups based on length in
study (see Figure 1) are summarized in Table 1. The 3-year
completers differed significantly from the whole group in
terms of age, MMSE and ADAS-Cog, but not sex distribu-BMC Neurology 2009, 9:7 http://www.biomedcentral.com/1471-2377/9/7
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tion, illness duration or APOE (t- and χ2 tests). Numeri-
cally the differences in the means were small and clinically
non-significant as defined by Cohen [28], except for
ADAS-Cog (around 0.3 SD).
These initial subject characterizations and the analyses in
the following subsection on MMSE and ADAS-Cog are
intended as a preamble to the main issue of this report,
the identification and analyses of cognitive domains.
MMSE and ADAS-Cog
Means ± SD for the MMSE sumscore, and medians and
quartiles for the ten MMSE items, over time are presented
in Table 2. The decline over the three years was 3.9 MMSE
points, corresponding to an annual decline of 1.3 points.
Homogeneity for the instruments is a measure of the
"overall correlation among the items", it was analysed in
order to study the statistical properties prior to the factor
analyses (which are affected by the homogeneity). Homo-
geneity for the MMSE items was estimated by Cronbach's
alpha for session 1, 5 and 8. For session 1 and 5, three
items with extreme distribution were not entered. For ses-
sion 1, alpha was .58, for session 5, it was .68 and for ses-
sion 8 (all items included) alpha was .76. For all analyses
there were no items that displayed a substantially lower
correlation with the sumscore than the others.
Means ± SD for the ADAS-Cog sumscore and medians and
quartiles for the eleven standard items plus the two addi-
tional items, over time are presented in Table 3. Cron-
bach's alpha for the ADAS-Cog data (all 13 items) for
session 1, 4 and 7 was .79, .89 and .94, respectively.
Factor analyses and construction of cognitive domains
Factor analyses were conducted in order to objectively
study how many, and the nature of, different dimensions
(factors) that are detectable among the item scores, and
which items that belong to (load on) those factors, to ena-
Patient flow through the study, frequencies Figure 1
Patient flow through the study, frequencies. Circled numbers represent the groups based on length in study.
Study
entry
6
months
1
year
2
years
3
years
435
14 93 93 39 38
158 251 344 383 421
Study
entry
only
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pleters
1-year
com-
pleters
2-year
com-
pleters
3-year
com-
pleters
Excluded
subjects
Table 1: Study entry characteristics for groups classified by length in study
Characteristic Study entry only 6-month completers 1-year completers 2-year completers 3-year completers Total SATS sample
N 38 39 93 93 158 435
Sex (men) 31.6% 25.6% 32.3% 45.2% 35.4% 35.2%
Age (years) 75.8 ± 4.67 77.7 ± 4.17 74.7 ± 6.21 74.2 ± 6.87 73.8 ± 6.99 74.6 ± 6.53
Duration (yrs) 3.43 ± 2.38 2.92 ± 1.53 3.08 ± 2.04 3.13 ± 2.15 3.11 ± 2.61 3.11 ± 2.26
APOE ε4 allelea 69.7% 60.0% 74.7% 61.5% 63.9% 66.0%
MMSE 21.7 ± 4.01 20.9 ± 4.49 21.6 ± 5.18 22.0 ± 4.21 23.1 ± 4.15 22.0 ± 4.55
ADAS-Cog (70) 22.9 ± 10.7 22.7 ± 9.26 21.9 ± 11.2 21.9 ± 9.89 18.2 ± 9.03 20.7 ± 10.0
ADAS-Cog (85) 32.6 ± 12.6 32.2 ± 10.9 30.7 ± 12.8 31.3 ± 11.4 26.8 ± 10.8 30.0 ± 11.8
Note. Values are presented as Mean ± SD or percent, a Percentage carrying at least one APOE ε4 allele.BMC Neurology 2009, 9:7 http://www.biomedcentral.com/1471-2377/9/7
Page 5 of 12
(page number not for citation purposes)
ble construction of domains based on those items. Multi-
ple analyses were conducted to obtain more confident
factor structures and to compare different time sessions.
In a first step, all MMSE and ADAS-Cog items for the same
individual and session were entered into a database that
contained 1867 such data sets. A factor analysis using Pro-
max rotation was performed on that database. This analy-
sis yielded three factors with Eigenvalues over 1 (10.6,
1.92 and 1.16 for factors 1, 2 and 3, respectively). Factor 1
was loaded by many variables and seems to reflect general
cognitive performance, Factor 2 seems to reflect declara-
tive memory, and Factor 3 seems to reflect spatial and
praxis aptitudes.
Then, we performed similar factor analyses on the MMSE
and ADAS-Cog items from each session at a time. The
study entry session contained 421 complete cases, the fol-
lowing sessions a decreasing number of patients, with 146
cases in the last session. The pattern of Eigenvalues and
factor loadings from the first two sessions were different
from the following five, which yielded similar patterns as
Table 2: Central and variation measures for MMSE items and sumscores for the eight assessments
Test Max score Study entry 2 months 6 months 12 months 18 months 24 months 30 months 36 months
MMSE Items
Orientation 10 8 (6, 9) 8 (7,10) 8 (6, 9) 7 (6, 9) 7 (5, 9) 6 (4, 8) 6 (4, 8) 6 (3, 8)
Registration 3 3 (3, 3) 3 (3, 3) 3 (3, 3) 3 (3, 3) 3 (3, 3) 3 (3, 3) 3 (3, 3) 3 (3, 3)
Attention 5 5 (3, 5) 5 (3, 5) 5 (4, 5) 5 (3, 5) 5 (3, 5) 4 (2, 5) 4 (2, 5) 3 (1, 5)
Recall 3 0 (0, 1) 0 (0, 2) 0 (0, 1) 0 (0, 1) 0 (0, 1) 0 (0, 1) 0 (0, 1) 0 (0, 1)
Naming 2 2 (2, 2) 2 (2, 2) 2 (2, 2) 2 (2, 2) 2 (2, 2) 2 (2, 2) 2 (2, 2) 2 (2, 2)
Repetition 1 1 (0, 1) 1 (1, 1) 1 (1, 1) 1 (1, 1) 1 (1, 1) 1 (1, 1) 1 (1, 1) 1 (0, 1)
Comprehension 3 3 (2, 3) 3 (3, 3) 3 (3, 3) 3 (2, 3) 3 (2, 3) 3 (2, 3) 3 (2, 3) 3 (2, 3)
Reading Ability 1 1 (1, 1) 1 (1, 1) 1 (1, 1) 1 (1, 1) 1 (1, 1) 1 (1, 1) 1 (1, 1) 1 (1, 1)
Writing Ability 1 1 (1, 1) 1 (1, 1) 1 (1, 1) 1 (1, 1) 1 (1, 1) 1 (1, 1) 1 (1, 1) 1 (0, 1)
Visual Constr. 1 1 (0, 1) 1 (0, 1) 1 (0, 1) 1 (0, 1) 1 (0, 1) 1 (0, 1) 0 (0, 1) 0 (0, 1)
MMSE Sumscores
MMSE, men 30 23.4 ± 4.24 24.3 ± 4.34 24.1 ± 4.49 23.0 ± 5.62 23.0 ± 6.07 22.3 ± 6.56 21.7 ± 7.27 20.4 ± 8.12
MMSE, women 30 22.9 ± 4.12 23.8 ± 3.89 23.8 ± 3.66 22.8 ± 4.21 21.6 ± 5.12 20.6 ± 5.74 19.6 ± 6.31 18.6 ± 6.81
MMSE, total 30 23.1 ± 4.15 24.0 ± 4.05 23.9 ± 3.97 22.9 ± 4.74 22.1 ± 5.50 21.2 ± 6.07 20.4 ± 6.72 19.2 ± 7.33
Note. Items are presented as Median (quartiles 25, 75), sumscores are presented as Mean ± SD. n = 118 for MMSE items and n = 158 (56 men and 
102 women) for MMSE sumscores.
Table 3: Central and variation measures for ADAS-Cog items and sumscores for the seven assessments
Test Max error Study entry 6 months 12 months 18 months 24 months 30 months 36 months
ADAS-Cog Items
Word Recall 10 6 (5, 7) 6 (5, 7) 6 (5, 7) 7 (5, 8) 6 (5, 8) 7 (5, 8) 7 (5, 8)
Naming 5 0 (0, 1) 0 (0, 1) 0 (0, 1) 0 (0, 1) 0 (0, 1) 0 (0, 1) 0 (0, 1)
Delayed Word Recalla 10 9 (7, 10) 9 (7, 10) 9 (7, 10) 10 (7, 10) 9 (7, 10) 10 (8, 10) 10 (8, 10)
Commands 5 0 (0, 1) 0 (0, 1) 0 (0, 1) 1 (0, 1) 1 (0, 2) 1 (0, 2) 1 (0, 2)
Constructional Praxis 5 1 (0, 1) 1 (0, 1) 1 (0, 1) 1 (0, 1) 1 (0, 2) 1 (0, 2) 1 (0, 3)
Ideational Praxis 5 0 (0, 1) 0 (0, 1) 0 (0, 1) 0 (0, 1) 0 (0, 1) 0 (0, 1) 0 (0, 2)
Orientation 8 1 (0, 3) 1 (0, 3) 2 (1, 4) 2 (0, 4) 3 (1, 4) 3 (1, 5) 4 (1, 5)
Word Recognition 12 5 (3, 8) 5 (3, 8) 5 (3, 9) 5 (3, 9) 6 (3, 9) 6 (3, 9) 8 (5, 11)
Remembering Test Instr. 5 1 (0, 1) 1 (0, 1) 1 (0, 2) 1 (0, 2) 1 (0, 3) 1 (0, 3) 1 (0, 3)
Spoken Language Ability 5 0 (0, 1) 0 (0,1) 0 (0, 1) 0 (0, 1) 0 (0, 1) 0 (0, 1) 0 (0, 1)
Word-finding Difficulty 5 1 (0, 1) 1 (0, 1) 0 (0, 1) 1 (0, 1) 1 (0, 1) 1 (0, 1) 1 (0, 2)
Comprehension 5 0 (0, 1) 0 (0, 1) 0 (0, 1) 0 (0, 2) 0 (0, 1) 1 (0, 2) 1 (0, 2)
Concentrationa 5 0 (0, 1) 0 (0, 1) 0 (0, 1) 0 (0, 1) 0 (0, 2) 0 (0, 1) 0 (0, 1)
ADAS-Cog Sumscores
ADAS-Cog, men 70 17.5 ± 10.0 16.6 ± 9.44 17.7 ± 11.6 19.3 ± 13.3 20.4 ± 14.3 21.5 ± 15.9 23.6 ± 18.0
ADAS-Cog, women 70 18.7 ± 8.45 19.1 ± 8.99 20.4 ± 10.2 22.5 ± 11.6 23.7 ± 11.6 26.3 ± 14.1 29.5 ± 15.7
ADAS-Cog, total 70 18.2 ± 9.03 18.2 ± 9.21 19.5 ± 10.7 21.4 ± 12.3 22.5 ± 12.7 24.6 ± 14.9 27.4 ± 16.8
Note. The scores at ADAS-Cog reflect number of errors. Items are presented as Medians (quartiles 25, 75), sumscores are presented as Mean ± 
SD. n = 100 for ADAS-Cog items and n = 158 (56 men and 102 women) for ADAS-Cog sumscores. a The items Delayed word recall and 
Concentration are not included in the standard ADAS-Cog (max 70 points).BMC Neurology 2009, 9:7 http://www.biomedcentral.com/1471-2377/9/7
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the comprehensive factor analysis. This probably reflects
that those patients who dropped out early were different
from the others.
All items displayed more or less deviant distributions
making it questionable to use a parametric type of factor
analysis. Results were therefore checked by applying the
non-parametric, latent class modeling factor analysis.
Findings were compatible, suggesting that the original
decomposition of the variance into the three factors was
valid.
We used the overall pattern to define to what domain each
item could be referred to, using a factor loading of 0.40 as
the lower limit. We computed new domain variables by
summing z-scores for study entry MMSE and ADAS-Cog
items according to which domain they belonged to, with
equal weight for all items (except a few with less convinc-
ing association with a specific factor, which we gave half
the weight). In order to obtain three comparable domain
variables, we performed z-transformations of the summed
z-scores, based on all subjects at study entry. These
domain variables displayed rather strong intercorrela-
tions, suggesting that the shared variance was around fifty
percent. In the following text, these cognitive domain var-
iables are denoted as (1) General domain, (2) Memory
domain and (3) Spatial domain. Table 4 shows the asso-
ciation of each item with the three domains (see Appendix
and Additional Files 1, 2and 3 for algorithms to compute
these domains).
Cognitive domains over time
The development over time measured by the three cogni-
tive domains, for the subgroups defined according to time
in study is shown in Figure 2. Inspection of the diagrams
suggests the following conclusions. The shorter a subject
remains in the study, the more poor appears the domain
scores at study entry to be, particularly the General and
the Memory domain scores. The Memory domain seems
to differ from the others by displaying no clear inverted U-
shape (quadratic effect) during the first year. The down-
ward slope of the lines appears to be less steep for the 3-
year completers. The other groups seem to accelerate in
deterioration before dropout.
These visual "conclusions" are tested below, by analyses
of variance (ANOVAs). Post hoc analyses are conducted to
analyse which groups differ significantly from each other.
For analysis of the three domains at study entry, one-way
ANOVAs were used to compare the groups based on
length in the study. The groups differed significantly in the
General and Memory domains (F(4, 420) = 4.02, p < .01
and F(4, 420) = 3.90, p < .01, respectively). Post hoc anal-
yses (with S-N-K protection for mass significances) were
non-significant, except for the Memory domain (3-year
completers differed from those who did not complete
even one year).
The development in the three domains over the first year
was analysed by one-way ANOVAs for repeated measures
(study entry, six months, one year) for the groups (1-year,
2-year and 3-year completers). For all domains, there were
both a linear (i.e. worsening over the year) and a quad-
ratic effect (i.e. a curve shaped like an inverted U). For the
General and Spatial domains the quadratic effect was larg-
est (F(1, 341) = 23.9, p < .001 and F(1, 341) = 38.3, p <
.001, respectively). For the Memory domain, the quad-
ratic effect was less pronounced (F(1, 341) = 8.56, p <
.01). There was also an interaction between group and
development over time for the General and Spatial
domains (p < .01 and p < .001, respectively), but not for
the Memory domain. Thus, the results for analyses over
the first year suggest that the cognitive performance as
measured by the General and Spatial domains was rela-
tively good at six months (the quadratic effect); in these
Table 4: List of MMSE and ADAS-Cog items that constitute the three cognitive domains
General domain Memory domain Spatial domain
m2 Registration m1 Orientation m3 Attention
m5a Naming m4 Recall m5c Comprehension (.5)
m5b Repetition (.5) a1 Word Recall Task m5e Writing Ability
m5c Comprehension (.5) a3 Delayed Word Recall m5f Visual Construction
m5d Reading Ability a7 Orientation a4 Commands (.5)
a2 Naming a8 Word Recognition a5 Constructional Praxis
a4 Commands (.5) a6 Ideational Praxis (.5)
a6 Ideational Praxis (.5)
a10 Spoken Language Ability
a11 Word-finding Difficulty
a12 Comprehension
a13 Concentration
Note. The code before each item indicates the succession number in our versions of the tests, m = MMSE and a = ADAS-Cog. The ".5" after an 
item indicates that the item contribute to its domain with half the weight.BMC Neurology 2009, 9:7 http://www.biomedcentral.com/1471-2377/9/7
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domains the groups also differed in development over
time.
Similar analyses of the regression lines from Year 1 to Year
2 for the 2-year and 3-year completers, for the three
domains, suggested that there was a highly significant and
linear deterioration over time for both groups and all
domains. However, for all domains, there were significant
differences between the 2-year and 3-year completers in
both level and slope.
Slope data, expressed as annual drop in domain scores
over the last six months before eventual drop out, for
groups according to time to drop out are provided in
Table 5. Comparisons among the groups, domain by
domain, by one-way ANOVAs showed that there were sig-
Domain scores over time for AD groups based on time in study Figure 2
Domain scores over time for AD groups based on time in study. Scores are shown for patients only participating at 
study entry (N = 38) and 6-month completers (N = 39) (Subfigure A), for 12-month completers (N = 93) (B), for 24-month 
completers (N = 93) (C) and for 36-month completers (N = 158) (D). Domain scores represent z-scores based on the study 
entry session for all patients. In subfigure A, study entry patients are shown to the left with no lines.
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nificant differences only for the spatial domain (F(3, 382)
= 3.87, p < .01). A post-hoc analysis was marginally signif-
icant (p = .052), and became significant if the 6-month
completers were omitted from the analysis (3-year compl-
eters differed from the other groups). The results verify the
statistical robustness of the visual impression of the dia-
grams.
Discussion
The patient group of this study can be characterized cog-
nitively as non-advanced in their AD (study entry mean
MMSE was 22). The homogeneity analyses of MMSE and
ADAS-Cog suggested that (a) items are reasonably
homogenous, limiting the possibility of identifying cogni-
tive profiles of individual subjects based on such indices,
and (b) the instruments, particularly MMSE, work better
for groups that are more advanced in their cognitive
reduction than the current group was at study entry. Still
there was a substantial heterogeneity among subjects
based on items. Compared to previous studies, MMSE was
somewhat less and ADAS-Cog was somewhat more
homogenous in our sample [26,29-32].
Even though homogeneity was high, a series of oblique
factor analyses on all MMSE and ADAS-Cog items
together yielded evidence for the presence of three repro-
ducible factors, which also appeared to be clinically rele-
vant. On the basis of the analyses, three cognitive
domains were constructed, (1) General domain, (2)
Memory domain and (3) Spatial domain.
The longer a subject remained in the study, the better were
the General and Memory domain scores at study entry.
The 6-month completers did not improve cognitively in
any domain. In the other groups, there was a six month
peak (operationalized as the quadratic component of the
effect of time during the first year, v.i.) in all domains, but
the effect in the Memory domain was less pronounced.
The reduction in performance from 12 to 24 months dif-
fered markedly between the 2- and 3-year completers even
if both groups deteriorated over time. A closer look at the
final six months before dropout in the different groups of
subjects suggests that once the speed of deterioration
within the Spatial domain is large enough, around 1
domain score per year, dropout is imminent.
The study is a prospective, naturalistic one, with virtues
and limitations typical of such studies. One virtue is the
representativity of patients seen in clinical practice and
thereby the potential for generalizability of the findings.
On the other hand, generalizability is compromised by
the substantial dropout rate; only 38% of the patients
could be followed over the three years. However, this is
not an unusually high dropout rate considering the illness
studied [9-11].
The three-year completers were younger and had better
cognitive scores at baseline. According to Wallin et al.
[21], who reported on the same material, those who
dropped out the first year were older, had lower MMSE at
baseline but did not differ in gender, duration, APOE or
ADAS-Cog at baseline.
The multiple causes of dropout makes it complicated to
analyse the clinical implications of differences between
groups according to length in study. Our intention was to
present our data as an example of cognitive course of AD
subjects in a clinical longitudinal study. There were sub-
stantial differences in the domain scores (level and rate of
decline) between the groups. These differences were
present already at study entry, but became larger over time
and most accentuated in the six months period before
dropout. This suggests that it is not necessarily so that a
study group followed for a long period is representative
for the whole sample even if it does not differ at study
entry.
The construction of domain scores based on factor analyses
of MMSE or ADAS-Cog is not common in the literature,
neither are factor analyses in general. Many researchers
have probably been discouraged to involve in such analyses
because of the high homogeneity of these instruments as
well as the skewed distributions on item level. Still, we per-
formed parametric analyses and were able to identify three
correlated but reproducible factors, in the combined MMSE
and ADAS-Cog data set. The factor pattern is similar to pat-
terns obtained in previous factor analytic studies of sepa-
rate MMSE or ADAS-Cog data using oblique rotation
[16,19,20]. Oblique rotation accepts correlated factors,
which are required due to the high homogeneity among the
items, probably resulting in factors more representative for
the subject characteristics. We checked the representativity
of the findings using a new non-parametric type of factor
analysis based on latent variables [27]. We created domains
by summing standardized item scores rather than using fac-
tor scores [20].
The segregation of the domain data over time suggests
that the factor analyses and subsequent allocation of
Table 5: Drop in the cognitive domains during the last six 
months for the groups
Domain
Group General Memory Spatial
6-month completers 1.106 0.700 0.477
1-year completers 1.032 0.428 0.809
2-year completers 1.361 0.520 1.078
3-year completers 0.669 0.330 0.426
Note. Slope is expressed as annual drop in z-scores.BMC Neurology 2009, 9:7 http://www.biomedcentral.com/1471-2377/9/7
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items to domains generated valid information. However,
the lack of similar analyses in the literature suggests that
the findings must be cross validated before they can be
regarded as robust.
An alternative would be to construct cognitive domains
based on a comprehensive neuropsychological battery,
which might result in more informative and less corre-
lated domains. However, as the cognitive deterioration
becomes more advanced, such assessment batteries may
become difficult to administer. Another reason to try to
base domains on MMSE and ADAS-Cog is that they are so
widespread and fast and easy to administrate; domains
constructed from them have potential to be of good use in
clinical practice as well as research.
In most groups there was a peak of the performance at six
months, the six month assessment was above the line
between the study entry and the twelve month assess-
ments, see Figure 2. We assumed that an untreated group
of AD patients would not suddenly improve their cogni-
tive functions on group level; therefore we assumed that
this six month peak may be regarded as an effect of treat-
ment (including placebo effects and possibly some prac-
tice effects). Since "treatment effect" may not be an
adequate expression lacking a control group, we just
denoted the phenomenon "six month peak". This six
month peak may be described as an inverted U-shape, sta-
tistically operationalized as the variance contribution of
the quadratic effect over the first year estimated by an
ANOVA for repeated measures.
One interesting finding is that the Memory domain did
not peak at six months as much as the other domains, and
also in other respects differed from the General and the
Spatial domains. One possible explanation is that the dis-
ease process has gone further with respect to memory
(hippocampal) functions already before initiation of
treatment than for cognitive domains with predominantly
neocortical localization. This theory has received some
support by earlier research [20,33]. For instance, memory
and spontaneous language items appear to be the earliest
indicators of AD, while praxis, commands and naming
items were sensitive later in the course of the disorder. It
is also evident from Tables 2 and 3 that memory items are
relatively impaired already at study entry. There may be
other mechanisms responsible for degeneration in hip-
pocampal structures, linked for instance to NMDA neuro-
toxicity, which are potentially amenable by drugs such as
memantine [34]. This is a good reason to use memory
assessment techniques that better reflects hippocampal
dysfunction.
As the cognitive domains are standardized based on the
study entry session data, an early relative impairment in
memory items, results in a Memory domain with less
potential for low scores. That is a negative consequence of
using clinical norm data and a reason not to be uncritical
when comparing the domains with each other, even
though they are standardized and based on the same data
set.
We have no good explanation why patients, who at study
entry did not differ much, could follow such different
courses. Turning the former argument up side down, the
deteriorating speed could become a useful clinical index.
Researchers have proposed definitions of rapid cognitive
decline in AD patients, based on the MMSE or ADAS-Cog
sumscores. However, such measures do not always corre-
spond to clinical decline as measured by other instru-
ments [35,36]. One alternative would be to construct
indices of cognitive decline within separate cognitive
domains rather than on sumscores, and based on as much
information as possible. We provide algorithms (Appen-
dix) for the three domains, which enable a clinician to
characterize an individual patient with respect to her/his
current status, relative our patients at study entry, and
compute slopes reflecting the speed of cognitive change.
In this way, better criteria (based on more information
and more homogenous information) can be established,
for instance for "rapid decliners" [36] .
As stated above, only few researchers have applied factor
analysis to MMSE and ADAS-Cog data. An alternative to
the factor analytic approach would be to directly focus
patient heterogeneity by using cluster analysis. In line
with this we will report on a re-analysis of the present
material using a non-parametric latent class cluster analy-
sis (Persson, Wallin et al, forthcoming).
Conclusion
The main finding of the present study is that MMSE and
ADAS-Cog data reflect three intercorrelated cognitive
domains, which differ in terms of the development over
time and possibly among patient groups. The overall
development of AD patients in this study included a cog-
nitive improvement at six months after ChEI onset that
was less pronounced in the Memory domain, followed by
a linear drop over time for the three domains. Groups
who remained longer in the study had somewhat better
initial performance and increased this advantage substan-
tially over time. This trajectory might reflect dropout
mechanisms rather than being a characteristic of groups of
AD patients with better prognosis. We provide algorithms
and an SPSS syntax file (see Appendix and additional files
1 to 3) for calculation of the three cognitive domains,
which may be used to assess the current status, decline
rate or drug treatment outcome in patients at clinics or
included in studies, against the background of the SATSBMC Neurology 2009, 9:7 http://www.biomedcentral.com/1471-2377/9/7
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material. The character of the SATS material is such that it
can be regarded as a kind of norm material of AD patients
in a rather early phase of the disease.
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Appendix: algorithms for calculation of cognitive 
domains
For SPSS users, a syntax file that can be used to automati-
cally calculate domain scores (and replace ADAS-3 and
ADAS-13) is available at the BMC Neurology website (see
additional files 1, 2 and 3).
To compute domain scores manually please start by calcu-
late z-values for the items with this algorithm:
z-itemx = (itemx - ax)/bx
where a and b for each item are found in Table 6.
Then, use the resulting z-items with the following algo-
rithms to calculate domain scores:
General domain (1) = (zmmse2 + zmmse5a +
0.5·zmmse5b + 0.5·zmmse5c + zmmse5d - zadas2 -
0.5·zadas4 - 0.5·zadas6 - zadas10 - zadas11 - zadas12 -
zadas13)/5.60
Memory domain (2) = (zmmse1 + zmmse4 - zadas1 -
zadas3 - zadas7 - zadas8)/4.43
Spatial domain (3) = (zmmse3 + 0.5·zmmse5c +
zmmse5e + zmmse5f - 0.5·zadas4 - zadas5 - 0.5·zadas6)/
3.53
Replacement of ADAS-3 and ADAS-13
Since the standard ADAS-Cog (max score 70) does not
comprise the items ADAS-3 and ADAS-13, we have pro-
vided simple algorithms to compute values that can
replace them.
Algorithm for replacement of ADAS-3:
Table 6: Item notations, variables for calculation of z-values and domain belongings
Item Notation a b Domain belonging
MMSE
Orientation mmse1 7.39 2.19 2
Registration mmse2 2.90 0.413 1
Attention mmse3 3.47 1.74 3
Recall mmse4 0.559 0.897 2
Naming mmse5a 1.97 0.178 1
Repetition mmse5b 0.756 0.430 1(.5)
Comprehension mmse5c 2.62 0.659 1(.5) and 3(.5)
Reading Ability mmse5d 0.975 0.157 1
Writing Ability mmse5e 0.841 0.366 3
Visual Construction mmse5f 0.563 0.497 3
ADAS-Cog
Word Recall Task adas1 6.36 1.68 2
Naming adas2 0.626 0.982 1
Delayed Word Recall adas3 8.31 2.10 2
Commands adas4 0.779 1.07 1(.5) and 3(.5)
Constructional Praxis adas5 0.955 0.896 3
Ideational Praxis adas6 0.636 0.979 1(.5) and 3(.5)
Orientation adas7 2.18 1.99 2
Word Recognition adas8 5.69 3.16 2
Remembering Test Instructions adas9a
Spoken Language Ability adas10 0.541 0.794 1
Word-finding Difficulty adas11 0.876 0.942 1
Comprehension adas12 0.812 0.927 1
Concentration adas13 0.729 1.00 1
Note. a adas9 is not included in any domain. "(.5)" after domain belonging indicates half weight.BMC Neurology 2009, 9:7 http://www.biomedcentral.com/1471-2377/9/7
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adas3 = 1.2·adas1 - 1.3·mmse4 + 2.2
Round to integer between 0 and 10 (e.g. the result 11.8
should be rounded to 10)
Algorithm for replacement of ADAS-13:
adas13 = 0.38·adas11 + 0.77·adas12 - 0.42
Round to integer between 0 and 5
These replacement algorithms were constructed aided by
step-wise linear regression analyses with all MMSE and
ADAS-Cog items as possible predictors (independent var-
iables) in a file with all complete test sessions for all
patients (n = 1887). The correlation between predicted
and actual value was r = .76 for ADAS-3, and r = .70 for
ADAS-13.
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